Anti-hIL-28a-IgG
-
Cat.code:
mabg-hil28a-3
- Documents
ABOUT
Neutralizing monoclonal antibody against human interleukin 28A
Anti-hIL-28a-IgG (clone 21C3) is a monoclonal antibody (mAb) for human interleukin 28A (hIL-28A). It is produced in hybridomas and purified by affinity chromatography. This antibody has been selected for its ability to efficiently neutralize the biological activity of hIL-28A. IL-28A (also known as interferon lambda 2) is a member of the type III interferon (IFN lambda) cytokine family that exhibits several common features with type I IFNs: antiviral activity and antitumor activity [1, 2].
Key features:
- A potent neutralizing mAb against hIL-28A
- Provided azide-free
- Each lot is functionally tested
References:
1. Donnelly RP. & Kotenko SV., 2010. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res. 30(8):555-64.
2. Li M. et al., 2009. Interferon-ls: the modulators of antivirus, antitumor, and immune responses. J. Leukoc. Biol., 86:23-32.
All products are for internal research use only, and not for human or veterinary use.
SPECIFICATIONS
Specifications
IL-28A
Human
No cross-reactivity with mouse IL-28A or mouse IL-28B.
Sodium phosphate buffer with glycine, saccharose and stabilizing agents
Neutralization assay
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:Anti-hIL-28a-IgG
-
Cat code:mabg-hil28a-3
-
Quantity:3 x 100 µg
Shipping & Storage
- Shipping method: Room temperature
- -20°C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
The IFN-λ family is essential to the antiviral response at epithelial barriers[1,2]. In humans, this family comprises four distinct proteins called IFN-λ1 (interleukin-29, IL-29), IFN-λ2 (IL-28A), IFN-λ3 (IL-28B), and the poorly secreted IFN-λ4. In mice, two functional orthologs (IL-28A and IL-28B) have been described. IFN-λs are produced when a viral infection is sensed by pattern recognition receptors. IFN-λs bind to a heterodimeric receptor formed by the assembly of IFN lambda receptor 1 (IFNLR1) and IL-10 receptor beta (IL10Rβ). This leads to the recruitment of the Janus kinases, JAK1 and TyK2, and phosphorylation of STAT1 and STAT2, which then dimerize and interact with IFN regulatory factor 9 (IRF9), forming the ISGF3 complex. ISGF3 binds to IFN-stimulated response elements (ISRE) in the promoters of IFN-stimulated genes (ISG) to regulate their expression.
1. Lazear HM. et al., 2015. Interferon-λ: Immune Functions at Barrier Surfaces and Beyond. Immunity. 43(1):15-28.
2. Lee S. & Baldridge MT., 2017. Interferon- Lambda: A Potent Regulator of Intestinal Viral Infections. Front Immunol. 8:749.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
